Kinarus Therapeutics Holding AG
SIX:KNRS

Watchlist Manager
Kinarus Therapeutics Holding AG Logo
Kinarus Therapeutics Holding AG
SIX:KNRS
Watchlist
Price: 15 CHF 416 566.67%
Market Cap: 19.5B CHF

Kinarus Therapeutics Holding AG
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Kinarus Therapeutics Holding AG
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Kinarus Therapeutics Holding AG
SIX:KNRS
Free Cash Flow
-CHf521k
CAGR 3-Years
-11%
CAGR 5-Years
7%
CAGR 10-Years
N/A
Wizz Air Holdings PLC
LSE:WIZZ
Free Cash Flow
€782.9m
CAGR 3-Years
50%
CAGR 5-Years
21%
CAGR 10-Years
N/A
No Stocks Found

Kinarus Therapeutics Holding AG
Glance View

Market Cap
19.5B CHF
Industry
Airlines

Kinarus Therapeutics Holding AG, a biopharmaceutical company based in Switzerland, emerges at the crossroads of innovative science and unmet medical needs. The company is committed to pioneering novel therapies for chronic disorders, with a strong focus on ophthalmology and fibrotic diseases. At the heart of its operations lies an unwavering dedication to developing pharmaceuticals that can significantly improve patients' lives. Kinarus employs a distinctive approach by repurposing existing drugs, thereby accelerating the development process and reducing the inherent risks associated with new drug development. This strategy allows the firm to quickly advance its candidates through clinical trials, capitalizing on existing safety profiles while innovating in therapeutic efficacy. The company's financial engine runs on a clinical-stage pipeline that harnesses the potential of drug candidates designed to tackle chronic and progressive conditions. Kinarus generates revenue primarily by advancing these candidates through different phases of clinical trials, aiming for favorable outcomes that will attract partnerships with larger pharmaceutical entities or lead to potential out-licensing agreements. As these collaborations materialize, Kinarus can secure milestone payments, royalties, and licensing fees, which feed back into its research and development endeavors. By striking a balance between scientific acumen and strategic partnerships, Kinarus Therapeutics continues to forge pathways in the biopharmaceutical sector, seeking not only to create financial value but also to deliver transformative solutions for enduring health challenges.

KNRS Intrinsic Value
Not Available

See Also

What is Kinarus Therapeutics Holding AG's Free Cash Flow?
Free Cash Flow
-521k CHF

Based on the financial report for Dec 31, 2023, Kinarus Therapeutics Holding AG's Free Cash Flow amounts to -521k CHF.

What is Kinarus Therapeutics Holding AG's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
7%

Over the last year, the Free Cash Flow growth was -24%. The average annual Free Cash Flow growth rates for Kinarus Therapeutics Holding AG have been -11% over the past three years , 7% over the past five years .

Back to Top